Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fit-for-Purpose Immunohistochemical Biomarkers.

Literature DB >> 29696583

Fit-for-Purpose Immunohistochemical Biomarkers.

Abstract

There are two aspects of immunohistochemistry (IHC) that are relevant to practicing pathologist: (1) understanding of IHC biomarker panels that are suitable for diagnostic, prognostic and predictive testing, and (2) understanding of IHC quality assurance (QA), which makes sure that the tests in these panels work as they should. The two aspects are closely linked together and call for collaborative approach between pathologists and IHC laboratory technologists as both need to be involved in developing and maintaining IHC biomarkers that are "fit-for-purpose". This article reviews the most current IHC QA concepts that are imminently material to practicing pathologists with emphasis on challenges that are specific to endocrine pathology.

Keywords: Biomarkers; Immunohistochemistry; Quality assurance; Validation

Mesh：

Substances：
Biomarkers

Year: 2018 PMID： 29696583 DOI： 10.1007/s12022-018-9529-4

Source DB: PubMed Journal: Endocr Pathol ISSN： 1046-3976 Impact factor: 3.943

48 in total

Review 1. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.

Authors: Jean W Lee; Michael Hall
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-11-18 Impact factor: 3.205

Review 2. Next generation immunohistochemistry: Emerging substitutes to genetic testing?

Authors: Juliana Andrici; Anthony J Gill; Jason L Hornick
Journal: Semin Diagn Pathol Date: 2017-06-27 Impact factor: 3.464

Review 3. Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors: Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova
Journal: J Mol Diagn Date: 2017-03-21 Impact factor: 5.568

Review 4. Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories.

Authors: Amy S Gargis; Lisa Kalman; Ira M Lubin
Journal: J Clin Microbiol Date: 2016-08-10 Impact factor: 5.948

5. Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry.

Authors: Carol C Cheung; Corrado D'Arrigo; Manfred Dietel; Glenn D Francis; Regan Fulton; C Blake Gilks; Jacqueline A Hall; Jason L Hornick; Merdol Ibrahim; Antonio Marchetti; Keith Miller; J Han van Krieken; Soren Nielsen; Paul E Swanson; Clive R Taylor; Mogens Vyberg; Xiaoge Zhou; Emina E Torlakovic
Journal: Appl Immunohistochem Mol Morphol Date: 2017-04

Review 6. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.

Authors: Rodrigo A Toledo; Nelly Burnichon; Alberto Cascon; Diana E Benn; Jean-Pierre Bayley; Jenny Welander; Carli M Tops; Helen Firth; Trish Dwight; Tonino Ercolino; Massimo Mannelli; Giuseppe Opocher; Roderick Clifton-Bligh; Oliver Gimm; Eamonn R Maher; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Patricia L M Dahia
Journal: Nat Rev Endocrinol Date: 2016-11-18 Impact factor: 43.330

Review 7. The use of biomarkers in neuroendocrine tumours.

Authors: Mohid Shakil Khan; Martyn E Caplin
Journal: Frontline Gastroenterol Date: 2013-03-21

8. Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors: Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal: Virchows Arch Date: 2015-09-17 Impact factor: 4.064

9. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.

Authors: Takeshi Yamaguchi; Takahiro Fujimori; Shigeki Tomita; Kazuhito Ichikawa; Hiroyuki Mitomi; Kazuya Ohno; Yosuke Shida; Hiroyuki Kato
Journal: Diagn Pathol Date: 2013-04-22 Impact factor: 2.644

Review 10. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis.

Authors: Vincent T Janmaat; Sophie H van Olphen; Katharina E Biermann; Leendert H J Looijenga; Marco B Bruno; Manon C W Spaander
Journal: PLoS One Date: 2017-10-23 Impact factor: 3.240

1 in total

1. Editorial: Special Issue on Immunohistochemical Biomarkers in Endocrine Pathology.

Authors: Lori A Erickson; Ozgur Mete
Journal: Endocr Pathol Date: 2018-06 Impact factor: 3.943

1 in total